Targeting STS: A Promising Strategy for Disease Treatment (P35725)

Target Name: Sialyltransferase

NCBI ID: P35725

Sialyltransferase

Other Name(s): None

Targeting STS: A Promising Strategy for Disease Treatment

Sialyltransferase (STS) is a group of enzymes that are involved in the transfer of sialic acid from one cell to another. These enzymes are essential for the development and maintenance of various tissues and organs, including the nervous system, gut, and immune system. STS has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting STS has become a promising strategy for the development of new treatments for a variety of diseases.

One potential drug target for STS is the STS-301, which is a small molecule inhibitor of the enzyme STS-2. STS-301 was developed by researchers at the University of California, San Diego and has been shown to be effective in preclinical studies in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another potential drug target for STS is the STS-401, which is a monoclonal antibody that targets the STS-1 enzyme. The STS-1 enzyme is involved in the production of sialic acid on the surface of many different types of cells, including immune cells and nerve cells. By blocking the activity of STS-1, the STS-401 has been shown to be effective in preclinical studies in treating autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

In addition to these drug targets, STS has also been identified as a potential biomarker for a variety of diseases. For example, researchers have shown that STS activity is highly correlated with the level of sialic acid on the surface of cancer cells. This suggests that STS could be a useful biomarker for tracking the effectiveness of cancer treatments. Additionally, STS has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that STS may be a useful target for developing new treatments for these conditions.

Overall, STS is a complex and important enzyme that plays a crucial role in the development and maintenance of many different tissues and organs. Targeting STS has the potential to lead to new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of STS in these processes and to develop safe and effective treatments.

Protein Name: Sialyltransferase (nonspecified Subtype)

The "Sialyltransferase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Sialyltransferase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets